Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombosis and malignancy: pathogenesis and prevention

J D Schwartz1, R Simantov

  • 1Department of Medicine, Cornell University Medical College, New York, NY 10021, USA.

In Vivo (Athens, Greece)
|January 19, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneous ozone effects on the DNA methylome of bronchial cells observed in a crossover study.

Scientific reports·2020
Same author

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Quantile causal mediation analysis allowing longitudinal data.

Statistics in medicine·2017
Same author

A DNA methylation biomarker of alcohol consumption.

Molecular psychiatry·2016
Same author

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Liver failure and mortality in HIV-positive haemophiliacs: FOURTEEN-YEAR EXPERIENCE AND LITERATURE REVIEW.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same journal

Time-Dependent Inflammatory Cytokine Responses in a Human Fetal Membrane Dual-Compartment Model.

In vivo (Athens, Greece)·2026
Same journal

Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study.

In vivo (Athens, Greece)·2026
Same journal

Nutritional Support for Treatment Continuity and Survival in Advanced Gastric Cancer: A Propensity Score-matched Study.

In vivo (Athens, Greece)·2026
Same journal

Efficacy of Switching from Prior Nonsteroidal Anti-inflammatory Drugs to Transdermal Diclofenac in Cancer Pain Management.

In vivo (Athens, Greece)·2026
Same journal

Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Attenuates the Aggressive Phenotype of Vulvar Squamous Cell Carcinoma Cells <i>In Vitro</i>.

In vivo (Athens, Greece)·2026
Same journal

Prognostic Value of Liver Function-based Scores in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation.

In vivo (Athens, Greece)·2026
See all related articles

Cancer patients have a higher risk of thrombosis due to malignancy. Prophylactic anticoagulation therapy can safely reduce thrombosis incidence in specific cancer patient groups, but further research into genetic risk factors is needed.

Area of Science:

  • Oncology
  • Hematology
  • Thrombosis Research

Background:

  • Cancer patients exhibit a significantly increased incidence of thrombosis, a condition observed for over a century.
  • The hypercoagulable state in malignancy arises from complex mechanisms, including coagulation cascade activation and tumor cell-induced alterations in blood components and endothelial cells.

Purpose of the Study:

  • To review the role of prophylactic anticoagulation therapy in mitigating thrombosis risk in cancer patients.
  • To identify the need for further research into genetic risk factors for thrombosis stratification in cancer.

Main Methods:

  • Literature review and analysis of existing studies on thrombosis in cancer patients.
  • Evaluation of the efficacy and safety of prophylactic anticoagulation in specific cancer patient cohorts.

Related Experiment Videos

Main Results:

  • Prophylactic anticoagulation therapy has demonstrated a safe reduction in thrombosis incidence among patients undergoing treatment for metastatic breast cancer.
  • Therapy also proved effective in reducing thrombosis in patients with upper extremity venous catheters.

Conclusions:

  • Prophylactic anticoagulation is a viable strategy for reducing thrombosis in select cancer patient populations.
  • Further investigation into newly identified genetic risk factors is crucial for accurate thrombosis risk stratification in cancer patients.